Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
BJU International|September 11, 2012
Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penisGiuseppe Di Lorenzo, Carlo Buonerba, Piera Federico, et al.
BMC Cancer|May 12, 2018
The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)Michele Guida, Stefania Tommasi, Sabino Strippoli, et al.
Clinical Colorectal Cancer|February 25, 2020
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)Evaristo Maiello, Gabriele Di Maggio, Stefano Cordio, et al.
World Journal of Gastroenterology|June 26, 2015
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX studyLorenzo Antonuzzo, Elisa Giommoni, Davide Pastorelli, et al.
Oncotarget|February 9, 2017
TRAP1 protein signature predicts outcome in human metastatic colorectal carcinomaFrancesca Maddalena, Vittorio Simeon, Giulia Vita, et al.
The Prostate|April 22, 2017
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abirateroneVincenza Conteduca, Orazio Caffo, Cristian Lolli, et al.
Oncotarget|July 14, 2016
Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinibCristian Lolli, Umberto Basso, Lisa Derosa, et al.
European Urology|October 2, 2010
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinomaGiuseppe Di Lorenzo, Carlo Buonerba, Piera Federico, et al.
Future Oncology (London, England)|July 24, 2014
Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patientsCarlo Buonerba, Piera Federico, Davide Bosso, et al.
Future Oncology (London, England)|May 7, 2014
Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinomaMaria Iole Natalicchio, Giuseppina Improta, Angela Zupa, et al.
Pageof 10